louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05955664: Evaluation of Diffusion Tensor Imaging and High Frequency 3D Endovaginal Ultrasound
Official title: Evaluation of Diffusion Tensor Imaging and High Frequency 3D Endovaginal Ultrasound (EVUS) in Understanding the Anatomy of the Pelvic Floor and Levator Ani Muscle Injury.
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: NA
Conditions: Pelvic Floor Dysfunction
Lead sponsor: University Hospitals of North Midlands NHS Trust
Sponsor class: OTHER
First posted: 2023-07-21
Enrollment: 20
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DIAGNOSTIC

Brief summary: To assess the feasibility of a novel MRI technique- diffusion tensor imaging with fibre tracking in understanding the anatomy of the pelvic floor and levator ani muscle injury. To compare this novel MRI technique with endocavity ultrasound in assessment of pelvic floor anatomy and deficiencies in patients with pelvic floor problems.

Detailed description: The study population is females with symptoms of pelvic floor dysfunction, and with suspected anatomical abnormalities of the pelvic floor muscles, for example following obstetric injury. The participants will be recruited to the study through Pelvic Floor and gynaecology Clinics. Each patient will undergo the same imaging investigations, pelvic floor MRI and three-dimensional high frequency internal ultrasound. As the MRI is regarded the gold standard examination in the assessment of the levator ani muscle (LAM), it will be used as reference in our study. A novel technique in MR imaging, which allows tracking of the pelvic floor muscle fibers, Diffusion Tensor Imaging (DTI) will be performed in addition to the standard scanning protocol. The investigator thinks that MRI with DTI is superior to routine MRI in visualization of LAM.

Moreover, every participant will undergo pelvic floor ultrasound (EVUS), which is believed to be comparable with routine MRI in diagnosis of LAM defects. The investigator hypothesize that this type of ultrasound is not inferior to MRI with DTI in visualizing pelvic floor muscles and their abnormalities.

All images will be assessed independently by two radiologists experienced in pelvic floor imaging, who will not be aware of each other's findings.

Eligibility criteria: Inclusion Criteria:

* patients with probable previous obstetric injury
* with symptoms of obstructed defecation
* other pelvic floor dysfunction

Exclusion Criteria:

* claustrophobic patients unable to undergo MRI scan
* patients with general contraindications to MRI
* patients not willing to take part in the study
* patients not able to consent
* pregnant patients
* patients unable to understand verbal and written English

Primary outcomes:
measure: Comparability of MRI to DTI
timeFrame: 7 hour visit time
Secondary outcomes:
Other outcomes:
Locations:
city: Stoke-on-Trent
country: United Kingdom
facility: University Hospital of North Midlands
state: Staffordshire
Study officials:
References:
Clinical trial NCT00883064: To Demonstrate the Relative Bioequivalence of Lisinopril 1 x 40 mg Tablets Under Fasting Conditions
Official title: Randomized, 2-Way Crossover, Bioequivalence Study of Eon Labs Manufacturing Inc. (USA) and Zeneca (USA) (Zestril) 40 mg Lisinopril Tablet Administered as a 1 x 40 mg Tablet in Health Adult Males Under Fasting Conditions.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Hypertension
Lead sponsor: Sandoz
Sponsor class: INDUSTRY
First posted: 2009-04-17
Enrollment: 32
Sex: MALE
Minimum age (years): 18
Maximum age (years): 54
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: To Demonstrate the Relative Bioequivalence of Lisinopril 1 x 40 mg Tablets Under Fasting Conditions.


Eligibility criteria: Inclusion Criteria:

* No clinically significant abnormal finding on physical exam, medical history, or clinical laboratory results on screening.

Exclusion Criteria:

* Positive test results for HIV or hepatitis B or C.
* Treatment for drug or alcohol dependence.

Primary outcomes:
measure: Bioequivalence based on AUC and Cmax
timeFrame: 23 days
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Anapharm
name: Eric Masson, Pharm.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01067664: Prognostic Value of Progesterone for In Vitro Fertilization (IVF) Outcome
Official title: The Effect of Serum Progesterone Levels on the Day of hCG Administration on the Probability of Pregnancy in Patients Treated by IVF Using GnRH Antagonists and Recombinant Gonadotrophins
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Subfertility
Lead sponsor: Aristotle University Of Thessaloniki
Sponsor class: OTHER
First posted: 2010-02-11
Enrollment: 130
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 39
Standard ages: ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Women undergoing ovarian stimulation with the use of rFSH and GnRH antagonists for in-vitro fertilization.

Brief summary: This observational study attempts to investigate the potential role of serum progesterone levels on the day of hCG administration (thus, the end of the follicular phase) on the probability of pregnancy, in patients undergoing IVF with the use of GnRH antagonists and recombinant gonadotrophins.

There has been evidence, that increased serum levels of progesterone are associated with a decreased probability of pregnancy after IVF.

This study will attempt to explore the role of progesterone on the outcome of IVF, by closely monitoring its levels during the late follicular phase.


Eligibility criteria: Inclusion Criteria:

* Age \< 40 years
* Basal FSH \< 12 IU/L
* Basal P \< 1.6 ng/mL

Exclusion Criteria:

* Presence of cystic formations at the ovaries during the basal ultrasound scan (prior the initiation of stimulation)
* Women with polycystic ovaries syndrome (PCOS)
* Women with Stage III-IV Endometriosis
* Women with a pathological condition of the adrenal glands

Primary outcomes:
measure: Clinical pregnancy, defined as ultrasound evidence of fetal heart activity at 6-8 weeks of gestation
timeFrame: At 6-8 weeks of gestation
Secondary outcomes:
measure: Pregnancy (defined as a b-hCG> 25 IU/L)
timeFrame: 12 days after embryo transfer
Other outcomes:
Locations:
city: Thessaloniki
country: Greece
facility: Unit for Human Reproduction, 1st Dept. of Obstetrics and Gynaecology, Medical School, Aristotle University of Thessaloniki
Study officials:
affiliation: 1st Dept. of Obstetrics and Gynaecology, Medical School, Aristotle University of Thessaloniki
name: Basil C Tarlatzis, MD, PhD
role: PRINCIPAL_INVESTIGATOR
affiliation: Unit for Human Reproduction, 1st Dept. of Obstetrics and Gynaecology, Medical School, Aristotle University of Thessaloniki
name: Christos A Venetis, MD, MSc
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00054964: Comparative Effectiveness of a Breath-operated Albuterol Inhaler in Asthma Patients With Poor Inhaler Technique
Official title: Comparison of Single-dose Efficacy of Albuterol-HFA-BOI and Albuterol-HFA-MDI in Asthmatics With Poor Inhaler Coordinating Ability
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Asthma
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.
Sponsor class: INDUSTRY
First posted: 2003-02-17
Enrollment: 14
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: This study was designed to examine the effectiveness of a breath-operated albuterol inhaler in asthma patients who have difficulty using their standard "press-and-breathe" inhaler.

Detailed description: This was a single-center, randomized, open-label, active-controlled, 2-period, 2-sequence, single dose-dose, crossover comparison of the ability of Albuterol BOI-HFA to produce bronchodilation relative to that produced by to albuterol MDI-HFA in at least 12 asthmatics with poor inhaler coordinating ability.

Eligibility criteria: Inclusion Criteria:

* Asthma diagnosed ≥6 months prior and stable for 4 weeks prior to screening
* Poor inhaler coordination as assessed at screening
* Reversible bronchoconstriction (≥ 12% increase in FEV1)

Exclusion Criteria:

* Albuterol allergy
* Investigational drug within 30 days
* Injected corticosteroid within 6 weeks
* Requires beta-blockers, MAO inhibitors, tricyclic antidepressants, long-acting beta-blockers, steroids other than those inhaled
* Other criterial apply

Primary outcomes:
measure: Percent change in SGaw (A measure of the change in specific airway conductance - how hard it is to get air into the lungs)
timeFrame: Pre-dose and +120 minutes
Secondary outcomes:
measure: The area-under-the-effect curve of change in SGaw from basline over time
timeFrame: Pre-dose and +120 minutes
measure: The maximum increase in SGaw from baseline over two hours
timeFrame: Baseline through +120 minutes
measure: Time in hours to the maximum increase in SGaw from baseline
timeFrame: Baseline through +120 minutes post-dose
Other outcomes:
Locations:
city: Denver
country: United States
facility: National Jewish Medical and Research Ceter
state: Colorado
Study officials:
affiliation: National Jewish Medical Center
name: Harold Nelson, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Nelson HS, Wenzel SE, Weisfeld L, Llorens L, Atkinson DC, Stahl EG. Comparison of single-dose efficacy of albuterol-hydrofloroalkane breath-activated inhaler and Nelson HS, Wenzel SE, Weisfeld L, Llorens L, Atkinson DC, Stahl EG. Comparison of single-dose efficacy of albuterol-hydrofloroalkane metered-dose inhaler in asthma patients with poor inhaler coordinating ability. Chest 2008;134:92003S (Abstracts, ACCP Annual Meeting, October 25-30, 2008, Philadelphia, Pennsylvania, USA.
Clinical trial NCT06005064: Middle Age muScle Krill Study
Official title: The Effect of Krill Oil Supplementation on Muscle Function and Mass in Middle-aged Adults: A Randomised Controlled Trial
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Sarcopenia
Keywords: Krill oil
Muscle strength
Muscle mass
Middle-aged
Lead sponsor: University of Glasgow
Sponsor class: OTHER
First posted: 2023-08-22
Enrollment: 92
Sex: ALL
Minimum age (years): 35
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: 1:1 basis
Primary purpose: PREVENTION

Brief summary: This study will determine the effect of 6 months of supplementation with krill oil on muscle strength and mass in middle-aged adults. The study hypothesis is that krill oil supplementation will increase muscle strength and mass in middle-aged adults.


Eligibility criteria: Inclusion Criteria:

* Be 35-60 years old
* Have a BMI of less than 35kg/m2

Exclusion Criteria:

* People with diabetes, severe cardiovascular disease, seizure disorders, uncontrolled hypertension (\>150/90mmHg at baseline measurement), cancer or cancer that has been in remission \<5 years, ambulatory impairments which would limit the ability to perform assessments of muscle function, dementia, on anticoagulant therapy, and/or taking medication known to affect muscle (e.g., steroids).
* People who have allergies to seafood, and/or regular consumption of more than 1 portion of oily fish per week.
* People who perform regular (\>1 day/week) resistance exercise training.

Primary outcomes:
measure: Change in knee extensor maximal isometric torque ( MVC)
timeFrame: Change from baseline to 24 weeks
Secondary outcomes:
measure: Change in fat mass
timeFrame: Change from baseline to 24 weeks
measure: Change in lean mass
timeFrame: Change from baseline to 24 weeks
measure: Change in omega-3 levels
timeFrame: Change from baseline to 24 weeks
measure: Change in Grip strength
timeFrame: Change from baseline to 24 weeks
measure: Change in Muscle thickness
timeFrame: Change from baseline to 24 weeks
Other outcomes:
measure: Change in systemic inflammation
timeFrame: Change from baseline to 24 weeks
measure: Change in muscle inflammation
timeFrame: Change from baseline to 24 weeks
measure: Change in muscle anabolic signalling
timeFrame: Change from baseline to 24 weeks
Locations:
city: Glasgow
country: United Kingdom
facility: University of Glasgow
Study officials:
References:
Clinical trial NCT01677364: Elective Induction vs Spontaneous Labour in Patients With Heart Disease
Official title: ELECTIVE INDUCTION OF LABOUR VS SPONTANEOUS LABOUR IN WOMEN WITH HEART DISEASE - A PROSPECTIVE RANDOMIZED CONTROLLED TRIAL
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Heart; Disease,Complicating Pregnancy, Pre-existing
Keywords: induction of labour
heart disease patients
Lead sponsor: PIMERIndia
Sponsor class: UNKNOWN
First posted: 2012-09-03
Enrollment: 50
Sex: FEMALE
Minimum age (years): 19
Maximum age (years): 37
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Fifty pregnant patients with acquired and congenital heart disease between 38-41 weeks were randomised into elective induction and spontaneous labour groups only after bishop score was equal to or more than 6.It was concluded that induction of labour with oxytocin is a relatively safe procedure in women with low risk heart disease with NYHA class I and II. It resulted in a similar caesarean delivery rate and was not associated with more maternal and neonatal complications.

Detailed description: Induction of labour was done with oxytocin. An infusion of 30U oxytocin diluted in 500ml normal saline was prepared and given through infusion pump at initial rate of 3mU/min. Subsequently dose was increased 3mU/min every 45 min till adequate uterine contractions were established.

Epidural analgesia was provided wherever feasible or Injection Morphine 2-5mg was given intravenously for pain relief.

Eligibility criteria: Inclusion Criteria:

* NYHA class I-II
* cephalic presentation
* singleton gestation

Exclusion Criteria:

* previous cesarean section,
* Primary pulmonary hypertension,
* Eisenmenger syndrome,
* Marfan syndrome,
* Left heart obstruction,
* Prior cardiac event or arrhythmia,
* Malformed fetus,
* Severe anemia (\<7g/dl),
* Intrauterine fetal death,
* other obstetrical indications for induction of labour
* patients on anticoagulation.

Primary outcomes:
measure: Duration of labour
timeFrame: at the time of delivery
measure: Rate of caesarean section
timeFrame: at the time of delivery
measure: Number of patients with delivery during workday hours
timeFrame: at the time of delivery
Secondary outcomes:
measure: number of patients with maternal complications
timeFrame: day 5
measure: number of patients with adverse neonatal outcome
timeFrame: day 5
Other outcomes:
Locations:
city: Chandigarh
country: India
facility: Post Graduate Institute of Medical Education and Research
Study officials:
References:
Clinical trial NCT06535464: Hypotension Prediction Index (HPI) in Patients Undergoing Robotic Assisted Radical Prostatectomy
Official title: Hypotension Prediction Index (HPI) in Patients Undergoing Robotic Assisted Radical Prostatectomy
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Hypotension During Surgery
Lead sponsor: University of Foggia
Sponsor class: OTHER
First posted: 2024-08-02
Enrollment: 80
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: SEQUENTIAL
Primary purpose: PREVENTION

Brief summary: Robot assisted radical prostatectomy (RARP) is the leader in robotic treatment for prostate cancer. Goal-directed therapy (GDT) is the approach used, but HPI, a machine learning algorithm analysing arterial waveforms, might offer additional benefits. The aim of this prospective randomised study is to evaluate the cumulative amount of intraoperative arterial hypotension episodes in patients undergoing RARP managed by GDT protocol guided or not by HPI algorithm


Eligibility criteria: Inclusion Criteria:

* all consecutive patients undergoing RARP; American Society of Anaesthesiology (ASA) SCORE I-III

Exclusion Criteria:

* Body Mass Index (BMI) of 18.5 to 35, uncontrolled arrhythmias, myocardial infarction or ischemic/hemorrhagic stroke in the last 6 months, III/IV stage Global Initiative for Chronic Obstructive Lung Disease, pulmonary fibrosis, contraindication to radial artery cannulation.

Primary outcomes:
measure: cumulative amount of time spent in Hypotension
timeFrame: intraoperative
Secondary outcomes:
Other outcomes:
Locations:
city: Foggia
country: Italy
facility: Ospedali Riuniti
state: Puglia
Study officials:
References:
Clinical trial NCT04221464: Development of a Clinical and Biological Database in Peritoneal Carcinosis (BCB CARCINOSE)
Official title: Development of a Clinical and Biological Database Monocentric and Prospective in Peritoneal Carcinosis
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Cancer
Peritoneal Carcinosis
Lead sponsor: Institut du Cancer de Montpellier - Val d'Aurelle
Sponsor class: OTHER
First posted: 2020-01-09
Enrollment: 600
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: OTHER

Brief summary: The creation of a prospective clinical-biological base dedicated to peritoneal carcinosis must therefore be able to serve as a support for this essential search for transfer.

Detailed description: The main objective is to improve the knowledge of carcinosis mechanisms to develop a specific treatment.

That's why this blood collection and tissue collection is very important for the future, these collection will be permitted to the scientists to develop a research specially for carcinosis.

Eligibility criteria: Inclusion Criteria:

* Patient over the age of 18;
* Patient managed for peritoneal carcinosis : digestives origins (pancreatic, gastroesophageal junction, colorectal, bowel) or peritoneum cancer
* Patient eligible for a peritoneal carcinosis treatment : at least one (or more) surgery (s) ;chemotherapy or any treatment for this disease
* Patient agree will all study procedure : biological samples \& tissues samples
* Patient giving informed consent

Exclusion Criteria:

* Patient not affiliated to Social Protection system
* Patient unable to understand or comply with study instructions or requirements for psychological, family, social or geographical reasons
* The level of French is insufficient to consent to the study and to response to the questionnaires
* Patient under guardianship
* Pregnancy ou breast-feeding women
* Patient treated in case of an emergency

Primary outcomes:
measure: Proportion of patients who gave their consent to participate in the study
timeFrame: Until the study completion: 4 years
Secondary outcomes:
Other outcomes:
Locations:
city: Montpellier
country: France
facility: Institut du cancer de Montpellier ICM
Study officials:
affiliation: Institut régional du cancer de Montpellier
name: François QUENET,MD
role: STUDY_CHAIR
References:
Clinical trial NCT00490464: Safety and Efficacy of Nicardipine for the Control of Blood Pressure After SAH
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Subarachnoid Hemorrhage
Intracerebral Hemorrhage
Keywords: Patients with SAH or ICH
Lead sponsor: University of Illinois at Chicago
Sponsor class: OTHER
First posted: 2007-06-22
Enrollment: 163
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: DEFINED_POPULATION
Time perspective: PROSPECTIVE

Brief summary: The purpose of this research is to explore ways to improve and simplify control of blood pressure in patients with SAH or ICH. This research will be done by comparing tow different medications that are routinely used to help control blood pressure. None of the medications used in this study nor any procedures performed are experimental.


Eligibility criteria: Inclusion Criteria:

* 18-70 years old (inclusive)
* Admission to NSICU with a diagnosis of SAH or ICH

Exclusion Criteria:

* Patients who are admitted \>48 hours after SAH or ICH
* Readmission or second SAH
* Readmission or second ICH
* Large (immediately life threatening) associated intraparenchymal or intraventricular hemorrhage
* Women who are pregnant

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Chicago
country: United States
facility: University of Illinois at Chicago, UIC
state: Illinois
Study officials:
affiliation: University of Illinois at Chicago, Department of Neurosurgery
name: Ben Z Roitberg, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00187564: Pilot Study on the Effect of Oral Controlled-Release Alpha-Lipoic Acid on Oxidative Stress in Adolescents With Type 1 Diabetes Mellitus
Official title: Pilot Study on the Effect of Oral Controlled-Release Alpha-Lipoic Acid on Oxidative Stress in Adolescents With Type 1 Diabetes Mellitus
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Diabetes Mellitus, Type 1
Keywords: Diabetes Mellitus, Type 1
lipoic acid
oxidative stress
Lead sponsor: University of California, San Francisco
Sponsor class: OTHER
First posted: 2005-09-16
Enrollment: 40
Sex: ALL
Minimum age (years): 8
Maximum age (years): 21
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The long-term effects of high blood sugar include blindness, kidney failure, and nerve damage that can ultimately cause loss of limbs. Research has shown that high blood sugar increases the amount of reactive oxygen species (ROS) produced in diabetics, and that the increase in ROS causes damage to eyes, kidneys, and nerves by a process called "oxidative stress." We postulate that alpha-lipoic acid, a potent anti-oxidant, can stop ROS from forming, thereby preventing long-term complications in diabetes. In this pilot study, we will be giving 30 teenagers with type 1 diabetes (T1D) controlled-release alpha-lipoic acid for 3 months, and comparing the amount of oxidative stress before and after treatment. Ten teenagers with T1D will receive placebo instead of alpha-lipoic acid and undergo the same research protocol to aid in validation of outcome measures.


Eligibility criteria: Inclusion Criteria:

1. Subjects must be pubertal (defined as Tanner stage II or greater), or post-pubertal, with an upper age limit of 21 years.
2. Subjects must have diabetes by 1997 ADA criteria:

   1. fasting plasma glucose \>= 126 mg/dL, or
   2. 2 hour postprandial glucose \>= 200 mg/dL
3. Subjects must have history of least one auto-antibody associated with T1D, either glutamic acid decarboxylase (GADA) or islet cell autoantigen 512 (ICA512), or history of diabetic ketoacidosis.

Exclusion Criteria:

1. Subjects must not have history of eye, kidney or nerve damage 2. Subjects must not be deemed unable or unlikely to comply with the protocol. Children who are unable to swallow pills, or are unwilling to take pills twice daily will be excluded from the study.

-

Primary outcomes:
measure: 1. protein carbonyl (measurement of oxidized protein)
measure: 2. Thiobarbituric Acid Reactive Substances (TBARS) (measurement of oxidized lipid)
measure: 3. 8-Oxo-dG/8-Oxo-dA (measurement of oxidized DNA)
measure: 4. Trolox equivalent antioxidant capacity (TEAC) (measurement of total antioxidant status)
Secondary outcomes:
measure: 1. Hb A1c
measure: 2. Urine albumin/creatinine ratio
Other outcomes:
Locations:
city: San Francisco
country: United States
facility: UCSF Division of Pediatric Endocrinology
state: California
Study officials:
affiliation: University of California, San Francisco
name: Stephen E Gitelman, MD
role: PRINCIPAL_INVESTIGATOR
References: